- Open
- 2.70
- High
- 3.45
- Low
- 2.48
- Close
- 2.61
- Change
- +0.20 (8.11%)
- Volume
- 4,232,960
| 15 Sept 2026 | 07:02:01 | New peer-reviewed publication |
| 15 Sept 2026 | 07:01:01 | P140 International Patent Filing Update |
| 15 Sept 2026 | 07:00:03 | Half-year Financial Report |
| 10 Sept 2026 | 13:40:14 | Holding(s) in Company |
| 10 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 1 Jan 2025 | Annual Report December 2014 |
ImmuPharma plc is a pharmaceutical company focused on the development and commercialization of novel drugs to treat serious medical conditions. It operates through collaborations with research institutions, such as the CNRS in France, and manages the clinical development of drug candidates. The company seeks partnerships to advance its product pipeline and maintains a lean corporate structure to control costs. ImmuPharma serves patients, healthcare professionals, and payers primarily in the pharmaceutical sector.
| 15 Sept 2026 | 07:02:01 | New peer-reviewed publication |
| 15 Sept 2026 | 07:01:01 | P140 International Patent Filing Update |
| 15 Sept 2026 | 07:00:03 | Half-year Financial Report |
| 10 Sept 2026 | 13:40:14 | Holding(s) in Company |
| 10 Jul 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 19 Jun 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 1 Jan 2025 | Annual Report December 2014 |
ImmuPharma plc is a pharmaceutical company focused on the development and commercialization of novel drugs to treat serious medical conditions. It operates through collaborations with research institutions, such as the CNRS in France, and manages the clinical development of drug candidates. The company seeks partnerships to advance its product pipeline and maintains a lean corporate structure to control costs. ImmuPharma serves patients, healthcare professionals, and payers primarily in the pharmaceutical sector.
| 10 Aug 2026 |
| 07:00:08 |
| Bioanalytical CRO partner for Kapiglucagon |
| 9 Apr 2026 |
| Rome Resources, Great Southern Copper, EGT, Active Energy, Immupharma, Astrid Intelligence |
| 9 Apr 2026 | Rome Resources, Great Southern Copper, European Green Transition, Active Energy, Immupharma, Astrid Intelligence - Small Cap Snapshot |
| 9 Apr 2026 | ImmuPharma: P140 partnering discussions continue; overwhelming backing for investment round |
| 27 Mar 2026 | ImmuPharma shares surge 20% as P140 partnering talks advance |
| 27 Mar 2026 | ImmuPharma advances P140 partnering talks as patent progress and new study data strengthen programme |
| 10 Aug 2026 |
| 07:00:08 |
| Bioanalytical CRO partner for Kapiglucagon |
| 9 Apr 2026 |
| Rome Resources, Great Southern Copper, EGT, Active Energy, Immupharma, Astrid Intelligence |
| 9 Apr 2026 | Rome Resources, Great Southern Copper, European Green Transition, Active Energy, Immupharma, Astrid Intelligence - Small Cap Snapshot |
| 9 Apr 2026 | ImmuPharma: P140 partnering discussions continue; overwhelming backing for investment round |
| 27 Mar 2026 | ImmuPharma shares surge 20% as P140 partnering talks advance |
| 27 Mar 2026 | ImmuPharma advances P140 partnering talks as patent progress and new study data strengthen programme |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £98m | -0.2% | |
| £71m | -0.9% | |
| £24m | +0.1% | |
IMMImmupharma plc | £16m | -0.7% |
| £7m | -0.7% | |
| £2m | -0.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £98m | -0.2% | |
| £71m | -0.9% | |
| £24m | +0.1% | |
IMMImmupharma plc | £16m | -0.7% |
| £7m | -0.7% | |
| £2m | -0.8% |